{
 "company": "flatiron-health",
 "as_of": "2026-09-27",
 "choices": [
  {
   "id": "flatiron-health-g01",
   "business": "Oncology real-world data for drugmakers and regulators",
   "category": "go_to_market",
   "dimension": "Listening tour",
   "statement": "Before settling on a product, the founders spent about two years interviewing clinicians and researchers, many met through Google Ventures introductions.",
   "event_date": "2012",
   "date_precision": "year",
   "evidence_kind": "participant_account",
   "sources": [
    "FH1"
   ]
  },
  {
   "id": "flatiron-health-g02",
   "business": "Community oncology software (OncoEMR and practice tools)",
   "category": "go_to_market",
   "dimension": "First customers",
   "statement": "Flatiron sold first to academic centers: Penn after more than a year of process, and Yale through physician-in-chief Tom Lynch.",
   "event_date": "2012",
   "date_precision": "year",
   "evidence_kind": "participant_account",
   "sources": [
    "FH1"
   ]
  },
  {
   "id": "flatiron-health-g04",
   "business": "Oncology real-world data for drugmakers and regulators",
   "category": "go_to_market",
   "dimension": "Early pharma pitch",
   "statement": "Pitched to Genentech, Flatiron heard that its technology was \"awesome\" but covered too few patients.",
   "event_date": "2013",
   "date_precision": "year",
   "evidence_kind": "participant_account",
   "sources": [
    "FH1"
   ]
  },
  {
   "id": "flatiron-health-p01",
   "business": "Community oncology software (OncoEMR and practice tools)",
   "category": "product",
   "dimension": "First product",
   "statement": "Flatiron built OncologyCloud, analytics that sat on top of cancer centers' existing EHR, billing and practice-management systems, in private beta at five East Coast hospital systems.",
   "event_date": "2013-01",
   "date_precision": "month",
   "evidence_kind": "company_described_offering",
   "sources": [
    "FH51"
   ]
  },
  {
   "id": "flatiron-health-p02",
   "business": "Community oncology software (OncoEMR and practice tools)",
   "category": "product",
   "dimension": "Early features",
   "statement": "Early OncologyCloud features were guideline-adherence monitoring, benchmarking, tumor-registry automation and real-time trial matching.",
   "event_date": "2013-01",
   "date_precision": "month",
   "evidence_kind": "company_described_offering",
   "sources": [
    "FH51"
   ]
  },
  {
   "id": "flatiron-health-g03",
   "business": "Community oncology software (OncoEMR and practice tools)",
   "category": "go_to_market",
   "dimension": "Community centers",
   "statement": "Flatiron moved toward community and non-university cancer centers, reaching about 20 by 2014.",
   "event_date": "2014",
   "date_precision": "year",
   "evidence_kind": "participant_account",
   "sources": [
    "FH1"
   ]
  },
  {
   "id": "flatiron-health-g06",
   "business": "Oncology real-world data for drugmakers and regulators",
   "category": "go_to_market",
   "dimension": "Chief medical officer",
   "statement": "Flatiron hired Amy Abernethy, who ran Duke's real-world evidence program, as chief medical officer.",
   "event_date": "2014",
   "date_precision": "year",
   "evidence_kind": "documented_offer_or_action",
   "sources": [
    "FH5"
   ]
  },
  {
   "id": "flatiron-health-g07",
   "business": "Oncology real-world data for drugmakers and regulators",
   "category": "go_to_market",
   "dimension": "First large pharma customer",
   "statement": "Flatiron began a collaboration with Pfizer.",
   "event_date": "2014",
   "date_precision": "year",
   "evidence_kind": "documented_offer_or_action",
   "sources": [
    "FH20"
   ]
  },
  {
   "id": "flatiron-health-p03",
   "business": "Community oncology software (OncoEMR and practice tools)",
   "category": "product",
   "dimension": "EHR acquisition",
   "statement": "Flatiron acquired Altos Solutions and its web-based OncoEMR, used by about 1,300 clinicians treating about 550,000 patients a year.",
   "event_date": "2014-05",
   "date_precision": "month",
   "evidence_kind": "documented_offer_or_action",
   "sources": [
    "FH2"
   ]
  },
  {
   "id": "flatiron-health-p04",
   "business": "Community oncology software (OncoEMR and practice tools)",
   "category": "product",
   "dimension": "Product boundary",
   "statement": "Flatiron kept OncoEMR and OncologyCloud as separate products and connected them.",
   "event_date": "2014-05",
   "date_precision": "month",
   "evidence_kind": "participant_account",
   "sources": [
    "FH3"
   ]
  },
  {
   "id": "flatiron-health-p05",
   "business": "Community oncology software (OncoEMR and practice tools)",
   "category": "product",
   "dimension": "Benchmarking plan",
   "statement": "Flatiron planned benchmarking for providers from de-identified data of other centers on the platform.",
   "event_date": "2014-05",
   "date_precision": "month",
   "evidence_kind": "company_described_offering",
   "sources": [
    "FH3"
   ]
  },
  {
   "id": "flatiron-health-p06",
   "business": "Oncology real-world data for drugmakers and regulators",
   "category": "product",
   "dimension": "Life-science tools",
   "statement": "Flatiron described a life-science tool for patient-to-trial matching and automated research data collection.",
   "event_date": "2014-05",
   "date_precision": "month",
   "evidence_kind": "company_described_offering",
   "sources": [
    "FH3"
   ]
  },
  {
   "id": "flatiron-health-g05",
   "business": "Oncology real-world data for drugmakers and regulators",
   "category": "go_to_market",
   "dimension": "Series B",
   "statement": "Flatiron raised a $130 million Series B led by GV and used about $100 million of it for the Altos purchase.",
   "event_date": "2014-05",
   "date_precision": "month",
   "evidence_kind": "documented_offer_or_action",
   "sources": [
    "FH2"
   ]
  },
  {
   "id": "flatiron-health-p09",
   "business": "Community oncology software (OncoEMR and practice tools)",
   "category": "product",
   "dimension": "Practice software reinvestment",
   "statement": "Flatiron funded next-generation OncoEMR, OncoBilling, the SeeYourChart portal and value-based-care tools.",
   "event_date": "2016-01",
   "date_precision": "month",
   "evidence_kind": "company_described_offering",
   "sources": [
    "FH6"
   ]
  },
  {
   "id": "flatiron-health-g08",
   "business": "Oncology real-world data for drugmakers and regulators",
   "category": "go_to_market",
   "dimension": "Roche investment",
   "statement": "Roche led a $175 million Series C alongside a multi-year non-exclusive agreement to buy Flatiron's life-science products.",
   "event_date": "2016-01",
   "date_precision": "month",
   "evidence_kind": "documented_offer_or_action",
   "sources": [
    "FH6"
   ]
  },
  {
   "id": "flatiron-health-g09",
   "business": "Oncology real-world data for drugmakers and regulators",
   "category": "go_to_market",
   "dimension": "FDA collaboration",
   "statement": "Flatiron signed a research collaboration with FDA's drug center on immunotherapy in advanced lung cancer.",
   "event_date": "2016-05",
   "date_precision": "month",
   "evidence_kind": "documented_offer_or_action",
   "sources": [
    "FH42"
   ]
  },
  {
   "id": "flatiron-health-p10",
   "business": "Community oncology software (OncoEMR and practice tools)",
   "category": "product",
   "dimension": "OCM tooling",
   "statement": "Flatiron offered tools inside OncoEMR for the Medicare Oncology Care Model, including quality dashboards and automated registry reporting.",
   "event_date": "2017-06",
   "date_precision": "month",
   "evidence_kind": "company_described_offering",
   "sources": [
    "FH37"
   ]
  },
  {
   "id": "flatiron-health-g10",
   "business": "Community oncology software (OncoEMR and practice tools)",
   "category": "go_to_market",
   "dimension": "OCM practices",
   "statement": "Flatiron became technology partner to about a third of Oncology Care Model practices, including Florida Cancer Specialists and Tennessee Oncology.",
   "event_date": "2017-06",
   "date_precision": "month",
   "evidence_kind": "company_described_offering",
   "sources": [
    "FH37"
   ]
  },
  {
   "id": "flatiron-health-g11",
   "business": "Oncology real-world data for drugmakers and regulators",
   "category": "go_to_market",
   "dimension": "Sale structure",
   "statement": "Flatiron was sold to Roche as a separate legal entity with segregated patient data, its own sales and marketing and a stated mandate to serve all partners.",
   "event_date": "2018-02-15",
   "date_precision": "day",
   "evidence_kind": "documented_offer_or_action",
   "sources": [
    "FH4"
   ]
  },
  {
   "id": "flatiron-health-g12",
   "business": "Oncology real-world data for drugmakers and regulators",
   "category": "go_to_market",
   "dimension": "Post-sale pharma deal",
   "statement": "Flatiron signed a three-year collaboration with Bristol-Myers Squibb weeks after the Roche deal.",
   "event_date": "2018-05",
   "date_precision": "month",
   "evidence_kind": "documented_offer_or_action",
   "sources": [
    "FH31"
   ]
  },
  {
   "id": "flatiron-health-p11",
   "business": "Oncology real-world data for drugmakers and regulators",
   "category": "product",
   "dimension": "Machine-learning triage",
   "statement": "Machine learning flagged charts (for example metastatic patients) for abstraction, with an abstractor confirming each result.",
   "event_date": "2018-09",
   "date_precision": "month",
   "evidence_kind": "company_described_offering",
   "sources": [
    "FH34"
   ]
  },
  {
   "id": "flatiron-health-p07",
   "business": "Oncology real-world data for drugmakers and regulators",
   "category": "product",
   "dimension": "Human abstraction",
   "statement": "Flatiron paid about 1,000 contractors to read clinicians' notes and turn them into research data.",
   "event_date": "2018-11",
   "date_precision": "month",
   "evidence_kind": "documented_offer_or_action",
   "sources": [
    "FH1"
   ]
  },
  {
   "id": "flatiron-health-p08",
   "business": "Oncology real-world data for drugmakers and regulators",
   "category": "product",
   "dimension": "Validation method",
   "statement": "Flatiron researchers replicated the control arms of existing clinical trials with its data more than a dozen times.",
   "event_date": "2018-11",
   "date_precision": "month",
   "evidence_kind": "participant_account",
   "sources": [
    "FH1"
   ]
  },
  {
   "id": "flatiron-health-g13",
   "business": "Oncology real-world data for drugmakers and regulators",
   "category": "go_to_market",
   "dimension": "Regulatory use",
   "statement": "Pfizer used Flatiron's breast-cancer database, among other data, in the application that extended Ibrance to men.",
   "event_date": "2019-04",
   "date_precision": "month",
   "evidence_kind": "documented_offer_or_action",
   "sources": [
    "FH12"
   ]
  },
  {
   "id": "flatiron-health-g14",
   "business": "Oncology real-world data for drugmakers and regulators",
   "category": "go_to_market",
   "dimension": "Shared endpoints",
   "statement": "Flatiron joined a Friends of Cancer Research pilot with rival data companies on shared endpoint definitions.",
   "event_date": "2019-11",
   "date_precision": "month",
   "evidence_kind": "documented_offer_or_action",
   "sources": [
    "FH22"
   ]
  },
  {
   "id": "flatiron-health-p13",
   "business": "Community oncology software (OncoEMR and practice tools)",
   "category": "product",
   "dimension": "Decision support",
   "statement": "Flatiron Assist clinical-decision support ran inside OncoEMR and also integrated with Epic.",
   "event_date": "2022-07",
   "date_precision": "month",
   "evidence_kind": "participant_account",
   "sources": [
    "FH19"
   ]
  },
  {
   "id": "flatiron-health-p15",
   "business": "Oncology real-world data for drugmakers and regulators",
   "category": "product",
   "dimension": "International data",
   "statement": "Flatiron built EHR-derived datasets outside the US through subsidiaries in Japan, Germany and the UK.",
   "event_date": "2022-07",
   "date_precision": "month",
   "evidence_kind": "participant_account",
   "sources": [
    "FH19"
   ]
  },
  {
   "id": "flatiron-health-g15",
   "business": "Oncology real-world data for drugmakers and regulators",
   "category": "go_to_market",
   "dimension": "International expansion",
   "statement": "Flatiron opened subsidiaries in Japan, Germany and the UK.",
   "event_date": "2022-07",
   "date_precision": "month",
   "evidence_kind": "participant_account",
   "sources": [
    "FH19"
   ]
  },
  {
   "id": "flatiron-health-p14",
   "business": "Oncology real-world data for drugmakers and regulators",
   "category": "product",
   "dimension": "Services",
   "statement": "Flatiron expanded from datasets into analytic, scientific and consulting services.",
   "event_date": "2023-05",
   "date_precision": "month",
   "evidence_kind": "company_described_offering",
   "sources": [
    "FH52"
   ]
  },
  {
   "id": "flatiron-health-g16",
   "business": "Oncology real-world data for drugmakers and regulators",
   "category": "go_to_market",
   "dimension": "FDA renewal",
   "statement": "Flatiron renewed its FDA collaboration for five years.",
   "event_date": "2023-09",
   "date_precision": "month",
   "evidence_kind": "documented_offer_or_action",
   "sources": [
    "FH13"
   ]
  },
  {
   "id": "flatiron-health-p12",
   "business": "Oncology real-world data for drugmakers and regulators",
   "category": "product",
   "dimension": "Audit trail",
   "statement": "Every abstracted data point is traceable through an audit trail to its source document in the EHR.",
   "event_date": "2024",
   "date_precision": "year",
   "evidence_kind": "company_described_offering",
   "sources": [
    "FH14"
   ]
  },
  {
   "id": "flatiron-health-p16",
   "business": "Oncology real-world data for drugmakers and regulators",
   "category": "product",
   "dimension": "LLM extraction",
   "statement": "Flatiron moved to LLM and NLP extraction validated against a decade of human-abstracted data.",
   "event_date": "2025-02",
   "date_precision": "month",
   "evidence_kind": "participant_account",
   "sources": [
    "FH32"
   ]
  },
  {
   "id": "flatiron-health-p17",
   "business": "Clinical research network",
   "category": "product",
   "dimension": "Divestiture",
   "statement": "Flatiron sold its clinical research business to Paradigm Health and kept OncoEMR.",
   "event_date": "2025-12",
   "date_precision": "month",
   "evidence_kind": "documented_offer_or_action",
   "sources": [
    "FH27"
   ]
  },
  {
   "id": "flatiron-health-g17",
   "business": "Clinical research network",
   "category": "go_to_market",
   "dimension": "Paradigm partnership",
   "statement": "The research network went to Paradigm with a multi-year partnership.",
   "event_date": "2025-12",
   "date_precision": "month",
   "evidence_kind": "documented_offer_or_action",
   "sources": [
    "FH27"
   ]
  }
 ]
}